Cy­to­ki­net­ics may walk a lone­ly road to mar­ket with tar­nished heart med ome­cam­tiv af­ter last part­ner bows out

Once flush with part­ners for heart fail­ure drug ome­cam­tiv mecar­bil, Cy­to­ki­net­ics watched its long­time al­ly Am­gen flee last month over weak da­ta from a Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.